Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Εμφάνιση άλλων εκδόσεων (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2001

Παρόμοια τεκμήρια

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Osteoprotegerin and the development of myeloma bone disease
ανά: Croucher, P, κ.ά.
Έκδοση: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
ανά: Vanderkerken, K, κ.ά.
Έκδοση: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Role of osteoprotegerin (OPG) in cancer.
ανά: Holen, I, κ.ά.
Έκδοση: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
ανά: Shipman, C, κ.ά.
Έκδοση: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

The role of osteoprotegerin in breast and prostate cancer
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
ανά: Shipman, C, κ.ά.
Έκδοση: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
ανά: Eaton, C, κ.ά.
Έκδοση: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
ανά: Anđelković Zlatibor, κ.ά.
Έκδοση: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
ανά: Huan Liu, κ.ά.
Έκδοση: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
ανά: Edwards, C, κ.ά.
Έκδοση: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
ανά: Eaton, C, κ.ά.
Έκδοση: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
ανά: Akshitha Devaraj, MBBS, κ.ά.
Έκδοση: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
ανά: Aiken Dao, κ.ά.
Έκδοση: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
ανά: Dongyeop Shin, κ.ά.
Έκδοση: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
ανά: Locklin, R, κ.ά.
Έκδοση: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
ανά: Waterman, E, κ.ά.
Έκδοση: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
ανά: Dongzheng Gai, κ.ά.
Έκδοση: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
ανά: Domingos Sousa, κ.ά.
Έκδοση: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
ανά: Dirk Hose, κ.ά.
Έκδοση: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
ανά: Lwin, S, κ.ά.
Έκδοση: (2017)